- seekingalpha.com
- Posted On 10 November 2026
Vir Biotechnology Stock: Fairly Valued After Phase 3 Success? (NASDAQ:VIR)
About six months ago, I wrote an article on Vir Biotechnology, Inc. ( VIR ) following their massive $1.7 billion collaboration agreement with Astellas Pharma. M...
Source:
seekingalpha.com